The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Quercetin for the Experimental Treatment of COVID-19
|
|
Author(s): Kunal Bhattacharya (NETES Institute of Pharmaceutical Science, India), Nongmaithem Randhoni Chanu (FPS, Assam Downtown University, India), Atanu Bhattacharjee (Royal School of Pharmacy, The Assam Royal Global University, India), Ripunjoy Bordoloi (NETES Institute of Pharmaceutical Science, India), Bhargab Jyoti Sahariah (NETES Institute of Pharmaceutical Science, India), Apurba Talukdar (NETES Institute of Pharmaceutical Science, India)and Ramen Kalita (NETES Institute of Pharmaceutical Science, India)
Copyright: 2021
Pages: 19
Source title:
Handbook of Research on Knowledge and Organization Systems in Library and Information Science
Source Author(s)/Editor(s): Barbara Jane Holland (Brooklyn Public Library, USA (retired) & Independent Researcher, USA)
DOI: 10.4018/978-1-7998-7258-0.ch004
Purchase
|
Abstract
The pandemic, which is brought about by the SARS CoV-2 infection, has inundated the entire world and obliterated the economies of numerous nations. Hence, looking for treatment and prophylaxis of COVID-19, Quercetin, which is a flavonoid gotten from plants and different sources like grapes, onion, tomatoes, apple, and so forth and has various properties like calming property, cardioprotective, and neuroprotective properties, is inspected for its antiviral properties, so it tends to be considered as one of the adjuvant medicines alongside the pharmacological medicines like Remdesivir and plasma treatment. A survey of the antiviral property of Quercetin from distributed articles proposes that Quercetin has a solid antiviral movement towards SARS C0V-2 and other upper respiratory tract infections. It can be securely and financially used to battle COVID-19. For high-hazard populaces, this medication can be a brilliant decision of treatment. Here the authors give proof to the utilization of Quercetin in relationship with pharmacological treatments like Remdesivir or improving plasma treatment.
Related Content
|
Elisha Mupaikwa, Kelvin Joseph Bwalya.
© 2024.
28 pages.
|
|
Nkholedzeni Sidney Netshakhuma.
© 2024.
21 pages.
|
|
Amrita Sarkar, Satyaki Sarkar.
© 2024.
27 pages.
|
|
Ahmad Said, Yulita Hanum P. Iskandar.
© 2024.
17 pages.
|
|
Manish Kumar.
© 2024.
19 pages.
|
|
Stansilas Bigirimana, Ganyanhewe Masanga.
© 2024.
22 pages.
|
|
Mampilo M. Phahlane.
© 2024.
20 pages.
|
|
|